<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199406</url>
  </required_header>
  <id_info>
    <org_study_id>Intense Trial</org_study_id>
    <nct_id>NCT01199406</nct_id>
  </id_info>
  <brief_title>Pain Reduction After Cholecystectomy</brief_title>
  <acronym>INTENSE</acronym>
  <official_title>Combined Preincisional Infiltration and Intraperitoneal Instillation of Levobupivacaine for Postoperative Pain Reduction After Laparoscopic Cholecystectomy; A Double-blind Placebo-controlled Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meander Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meander Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of combined intracutaneous infiltration and intraperitoneal
      instillation of 80 mL 0,125% levobupivacaine prior to the start of laparoscopic
      cholecystectomy on abdominal pain up to 24 hours after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of this study was postoperative abdominal pain as measured by a visual
      analogue scale (VAS), using a VAS lineal with a slide. The patient was asked to indicate a
      score from 0 to 100 corresponding to his or her pain. At 0.5, 2, 4, 8 and 24 hours after the
      surgical procedure the primary investigator visited the patient to obtain the VAS scores.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal Pain in Visual Analogue Scale (VAS 0-100mm)</measure>
    <time_frame>24 h postoperatively</time_frame>
    <description>Postoperative abdominal pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Shoulder pain</measure>
    <time_frame>24 h</time_frame>
    <description>Postoperative shoulder pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Analgesics</measure>
    <time_frame>24 h postoperatively</time_frame>
    <description>The need of rescue analgesics within the 24h postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events caused by the investigational procedure or by levobupivacaine itself</measure>
    <time_frame>Intra- and postoperative up to 24 hours</time_frame>
    <description>Adverse events were defined as neurological or cardial effects attributable to use of levobupivacaine. Adverse events by the procedure such as bleeding were also registered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Maximum two weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-operative complications including perforation of the gallbladder, bile duct injury, bowel injury and injury to vascular structures</measure>
    <time_frame>intraoperative, 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complications during hospitalisation</measure>
    <time_frame>during hospitalisation (up to two weeks)</time_frame>
    <description>Infection, bleeding, embolisation etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Cholecystolithiasis</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>80 mL 0.9% NaCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80mL 0.125% levobupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally</description>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <other_name>Chirocaine (brand name)</other_name>
    <other_name>NDA 20-997</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 18 and 80

          -  ASA I or II

          -  with symptomatic gallstone disease which requires elective laparoscopic
             cholecystectomy

        Exclusion Criteria:

          -  acute cholecystitis, cholangitis, severe acute pancreatitis, advanced liver cirrhosis
             or suspected gallbladder cancer,

          -  a medical history of epilepsy, cardiac arrhythmias or chronic pain of any kind, -
             allergy to amid type drugs

          -  pregnancy

          -  patients suffering from hypotension or hypovolemia

          -  infectious liver disease

          -  conditions obstructing adequate pain scoring

          -  patients using drugs that deduce function of the CYP3A4 or CYP1A2 system

          -  patients having an American Society of Anaesthesiologists (ASA) classification of
             three or higher.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner A Draaisma, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Meander MC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bart Hilvering, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meander MC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esther CJ Consten, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Meander MC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristine E Kofman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Meander MC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rene M Valk, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Meander MC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jarmila DW Van der Bilt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Meander MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meander MC</name>
      <address>
        <city>Amersfoort</city>
        <zip>3811ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>September 10, 2010</last_update_submitted>
  <last_update_submitted_qc>September 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>dr. Consten</name_title>
    <organization>Meander medical Center</organization>
  </responsible_party>
  <keyword>gallstone</keyword>
  <keyword>gallbladder</keyword>
  <keyword>cholecystectomy</keyword>
  <keyword>laparoscopic</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Cholecystolithiasis</mesh_term>
    <mesh_term>Cholelithiasis</mesh_term>
    <mesh_term>Gallstones</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

